(NASDAQ: CAPR) Capricor Therapeutics's forecast annual revenue growth rate of 87.15% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 82.71%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.57%.
Capricor Therapeutics's revenue in 2025 is $13,392,151.On average, 2 Wall Street analysts forecast CAPR's revenue for 2025 to be $272,016,001, with the lowest CAPR revenue forecast at $269,730,153, and the highest CAPR revenue forecast at $274,301,850. On average, 4 Wall Street analysts forecast CAPR's revenue for 2026 to be $5,243,737,033, with the lowest CAPR revenue forecast at $457,169,750, and the highest CAPR revenue forecast at $10,606,338,200.
In 2027, CAPR is forecast to generate $2,634,806,420 in revenue, with the lowest revenue forecast at $2,468,716,650 and the highest revenue forecast at $2,935,029,795.